SOURCE: Rheologics Technologies, Inc.

January 31, 2007 08:25 ET

Study: Blood Viscosity Shown to Be Elevated in Scleroderma Patients

EXTON, PA -- (MARKET WIRE) -- January 31, 2007 -- Rheologics Technologies, Inc. (PINKSHEETS: RTGI) ("Rheologics," the "Company"), the leader in the study of blood viscosity and its relationship to vascular diseases, announced today the results of a study performed at the University of Chicago using the Rheolog®, the Company's proprietary blood viscometer. The research demonstrated significantly higher blood viscosity in scleroderma patients over health controls and, among scleroderma patients, higher blood viscosity in patients having active digital (finger) ulcers over those scleroderma patients that did not.

Scleroderma, also called systemic sclerosis, is an autoimmune disease where the body's immune system attacks its own tissues, resulting in the formation of scar tissue and a hardening of the skin and internal organs. Women are more commonly affected than men, and patients are generally between the ages of 30 and 50. Approximately 300,000 people in the U.S. are affected with scleroderma.

Over 90 percent of scleroderma patients develop what is called Raynaud's phenomenon characterized by blue and red discoloration of the hands and often leading to painful digital (finger) ulcers. Although Raynaud's phenomenon is known to be closely related to the regulation of blood flow in the fingers, it is not yet understood why only some patients with scleroderma develop the ulcers. Furthermore, the root causes of scleroderma and also of Raynaud's phenomenon are not well understood.

The University of Chicago study included a healthy control group matched by age, gender, race and body-mass index and 33 randomly selected scleroderma patients. Among the scleroderma patients were those with active digital (finger) ulcers and those without. Using the Rheolog®, it was demonstrated that scleroderma patients with active digital ulcers had significantly higher blood viscosity than those without the ulcers. The difference was more pronounced in the low shear rate range of blood flow (i.e., under conditions where blood is moving slowly as in the microvessels). Overall, scleroderma patients had significantly higher blood viscosity than healthy controls.

Kenneth Kensey, MD, founder and Chief Scientific Officer of Rheologics, said, "The importance of blood viscosity is easily accepted by rheumatologists because they already use a parameter called erythrocyte sedimentation rate ('ESR' or 'sed' rate), which is a very primitive analog of the whole blood viscosity profiles generated by our Rheolog® device. This Chicago study demonstrates the importance of measuring blood viscosity in patients with scleroderma as a potential predictor of the onset of Raynaud's.

"Interestingly, we see a higher risk of heart attack and stroke in scleroderma patients, but what I believe is more important is that poor blood flow is being recognized as a common link driving a number of different diseases. Whether we are talking about the amputated fingers of a scleroderma patient, the amputation of the leg of a diabetic with peripheral vascular disease, glaucoma, macular degeneration, Alzheimer's or vascular dementia, or more generally, heart attacks and strokes, we need to understand thoroughly how the flow of blood impacts the progression of disease. While these diseases and many others are still incurable, understanding blood flow can help us greatly improve the quality of care we provide and the quality of life for our patients. Whole blood viscosity is the parameter that quantifies the blood's ability to flow and has the potential to unleash a wave of medical advances." Dr. Kensey is a cardiologist and the Chairman of Rheologics. As CEO of Kensey-Nash Corporation prior to founding Rheologics, he was responsible for the creation of interventional devices used today in hospitals around the world.

The Rheolog® is an IDE-exempt device approved for research and for providing additional information in the interpretation of disease.

About Rheologics Technologies, Inc.

Rheologics is committed to developing and commercializing innovative medical technologies that improve the diagnosis and treatment of human disease. The Company is accomplishing its mission by monitoring an overlooked basic physiological parameter -- whole blood viscosity. Rheologics believes that its innovations will ultimately enable the preventive diagnosis of diseases and the development of new cost-effective therapies that conquer today's most difficult medical problems, thereby improving the quality of life for millions of people worldwide. Further information on Rheologics may be found at

Cautionary Note Regarding Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the Company's beliefs and expectations about the performance and benefits of its technology; marketing and commercialization activities; and our beliefs regarding research and development efforts. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ. All forward-looking statements herein are based on information available to us as of the date hereof, and we undertake no obligation to update forward-looking statements to reflect events or circumstances occurring after this date.

Contact Information